MolecularMD Licenses Rights to Commercialize Technology Aimed at Endometrial Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD said today it has secured the rights to commercialize IP surrounding fibroblast growth factor receptor 2 activating mutations for diagnostic, prognostic, and predictive purposes in human endometrial cancer.

Rights to the IP are jointly held by Washington University in St. Louis and the Translational Genomics Research Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.